Riverbridge Partners’s AbbVie ABBV Stock Holding History

Riverbridge Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,061	Closed	-$319K	–	175
2023 Q4	$319K	Buy	2,061 +21	+1%	+$3.06K	﹤0.01%	168
2023 Q3	$304K	Hold	2,040	–	–	﹤0.01%	168
2023 Q2	$275K	Hold	2,040	–	–	﹤0.01%	170
2023 Q1	$325K	Hold	2,040	–	–	﹤0.01%	166
2022 Q4	$330K	Hold	2,040	–	–	0.01%	167
2022 Q3	$274K	Hold	2,040	–	–	﹤0.01%	175
2022 Q2	$312K	Hold	2,040	–	–	0.01%	172
2022 Q1	$331K	Hold	2,040	–	–	﹤0.01%	146
2021 Q4	$276K	Hold	2,040	–	–	﹤0.01%	157
2021 Q3	$220K	Hold	2,040	–	–	﹤0.01%	151
2021 Q2	$230K	Sell	2,040 -60	-3%	-$6.76K	﹤0.01%	153
2021 Q1	$227K	Buy	2,100 +60	+3%	+$6.42K	﹤0.01%	150
2020 Q4	$219K	Buy	+2,040	New	+$196K	﹤0.01%	147
2020 Q3	–	Sell	-2,140	Closed	-$210K	–	149
2020 Q2	$210K	Buy	+2,140	New	+$188K	﹤0.01%	143

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Riverbridge Partners's ABBV Position: Q1 2024 in Review

Riverbridge Partners sold out of AbbVie (ABBV) in Q1 2024, closing a stake of 2,061 shares — an estimated $319K sold.

Riverbridge Partners first reported a position in ABBV in Q2 2020 and held it in 14 quarters. The position peaked at $331K in Q1 2022. 3,379 funds tracked by Wall St. Rank hold ABBV as of Q1 2024.

Riverbridge Partners reported no remaining AbbVie position as of Q1 2024 after selling out during the quarter.
Riverbridge Partners sold 2,061 AbbVie shares in Q1 2024, an estimated $319K.
Riverbridge Partners first reported a position in AbbVie in Q2 2020 and held it in 14 quarters.
Riverbridge Partners's AbbVie position peaked at $331K in Q1 2022.
3,379 funds tracked by Wall St. Rank held AbbVie as of Q1 2024.

Based on Riverbridge Partners's 13F filing for Q1 2024, filed 26 Apr 2024.